Translational Stroke Research

, Volume 10, Issue 6, pp 719–728 | Cite as

Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia

  • Fenghua Chen
  • Zhongfang Weng
  • Qinghai Xia
  • Catherine Cao
  • Rehana K. Leak
  • Lihong Han
  • Jian Xiao
  • Steven H. Graham
  • Guodong CaoEmail author
Original Article


Our previous study indicated that nicotinamide phosphoribosyltransferase (NAMPT) is released from cells and might be an important extracellular neuroprotective factor in brain ischemia. Here, we tested whether NAMPT protects against ischemic brain injury when administered directly into the intracerebroventricular (ICV) compartment of the cranium. Recombinant NAMPT protein (2 μg) was delivered ICV in mice subjected to 45-min middle cerebral artery occlusion (MCAO), and the effects on infarct volume, sensorimotor function, microglia/macrophage polarization, neutrophil infiltration, and BBB integrity were analyzed. The results indicate that ICV administration of NAMPT significantly reduced infarct volume, retained its beneficial properties even when ICV administration was delayed by 6 h after MCAO, and improved neurological outcomes. NAMPT treatment inhibited pro-inflammatory microglia/macrophages, promoted microglia/macrophage polarization toward the anti-inflammatory phenotype, and reduced the infiltration of neutrophils into the perilesional area after brain ischemia. In vitro studies indicated that multiple pro-inflammatory microglial markers/cytokines were downregulated while multiple anti-inflammatory microglial markers/cytokines were induced in primary microglial cultures treated with NAMPT protein. NAMPT treatment also fortified the blood–brain barrier (BBB), as shown by reduced extravascular leakage of the small-molecule tracer Alexa Fluor 555 Cadaverine and larger-sized endogenous IgGs into brain parenchyma. Thus, NAMPT may protect against ischemic brain injury partly through a novel anti-inflammatory mechanism, which in turn maintains BBB integrity and reduces the infiltration of peripheral inflammatory cells. Taken together, these results provide validation of recombinant NAMPT delivery into the extracellular space as a potential neuroprotective strategy for stroke.


Brain ischemia Microglia/macrophages polarization Inflammation Neuroprotection BBB integrity NAMPT 



This project was supported by National Institutes of Health/NINDS grants NS079345 (to G.C.) and Department of Veterans Affairs Merit Review grants BX002346 and BX003923 (to G.C.). J.X. was supported by National Natural Science Foundation of China (81722028 and 81572237) and Natural Science Foundation of Zhejiang Province (R18H50001).

Compliance with Ethical Standards

All animal procedures used in this study were conducted in strict compliance with The National Institue of Health Guide for Use and Care of Laboratory Animals and approved by the University of Pittsburgh Institutional Animal Care and Use Committee.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12975_2019_692_MOESM1_ESM.docx (29 kb)
Supplemental Table 1 Animal number/group, animal exclusions and mortality for the entire project. Detailed information for animal number/group, the numbers that died, and reasons that animals died or were excluded from the experiment. (DOCX 29.1 kb)
12975_2019_692_MOESM2_ESM.docx (26 kb)
Supplemental Table 2 Primer sequences for real-time PCR. (DOCX 26 kb)
12975_2019_692_Fig6_ESM.png (55 kb)
Supplemental Figure 1

Effect of LPS contamination in recombinant NAMPT protein on infarct volumes after MCAO. Mice were subjected to MCAO and treated with ICV injections of NAMPT with or without LPS removal, and infarct volumes were determined with TTC staining 72 h after MCAO. PBS was used as the vehicle treatment control. Quantitative analysis showed that infarct reduction offered by NAMPT protein was negated by LPS contamination. ***p < 0.001 versus PBS treatment, ###p < 0.001 versus without LPS removal. N = 8, 9, 8 for PBS, NAMPT with or without LPS removal. (PNG 55 kb)

12975_2019_692_MOESM3_ESM.tif (2.8 mb)
High Resolution Image (TIF 2905 kb)


  1. 1.
    Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120:439–48.CrossRefGoogle Scholar
  2. 2.
    Chia NH, Leyden JM, Newbury J, Jannes J, Kleinig TJ. Determining the number of ischemic strokes potentially eligible for endovascular thrombectomy: a population-based study. Stroke. 2016;47:1377–80.CrossRefGoogle Scholar
  3. 3.
    Khaja AM, Grotta JC. Established treatments for acute ischaemic stroke. Lancet. 2007;369:319–30.CrossRefGoogle Scholar
  4. 4.
    Jing Z, Xing J, Chen X, Stetler RA, Weng Z, Gan Y, et al. Neuronal nampt is released after cerebral ischemia and protects against white matter injury. J Cereb Blood Flow Metab. 2014;34:1613–21.CrossRefGoogle Scholar
  5. 5.
    Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through sirt1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2011;69:360–74.CrossRefGoogle Scholar
  6. 6.
    Zhang W, Xie Y, Wang T, Bi J, Li H, Zhang LQ, et al. Neuronal protective role of pbef in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab. 2010;30:1962–71.CrossRefGoogle Scholar
  7. 7.
    Imai S. The nad world: a new systemic regulatory network for metabolism and aging--sirt1, systemic nad biosynthesis, and their importance. Cell Biochem Biophys. 2009;53:65–74.CrossRefGoogle Scholar
  8. 8.
    Magni G, Amici A, Emanuelli M, Raffaelli N, Ruggieri S. Enzymology of nad+ synthesis. Adv Enzymol Relat Areas Mol Biol. 1999;73:135–82 xi.PubMedGoogle Scholar
  9. 9.
    Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, et al. In vivo delivery of a bcl-xl fusion protein containing the tat protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci. 2002;22:5423–31.CrossRefGoogle Scholar
  10. 10.
    Zhang F, Xing J, Liou AK, Wang S, Gan Y, Luo Y, et al. Enhanced delivery of erythropoietin across the blood-brain barrier for neuroprotection against ischemic neuronal injury. Transl Stroke Res. 2010;1:113–21.CrossRefGoogle Scholar
  11. 11.
    Gan Y, Xing J, Jing Z, Stetler RA, Zhang F, Luo Y, et al. Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Stroke. 2012;43:3071–7.CrossRefGoogle Scholar
  12. 12.
    Chen Y, Balasubramaniyan V, Peng J, Hurlock EC, Tallquist M, Li J, et al. Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat Protoc. 2007;2:1044–51.CrossRefGoogle Scholar
  13. 13.
    Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, et al. Extracellular nicotinamide phosphoribosyltransferase (nampt) promotes m2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125:111–23.CrossRefGoogle Scholar
  14. 14.
    Denes A, Vidyasagar R, Feng J, Narvainen J, McColl BW, Kauppinen RA, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab. 2007;27:1941–53.CrossRefGoogle Scholar
  15. 15.
    Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849–57.CrossRefGoogle Scholar
  16. 16.
    Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci. 2007;27:2596–605.CrossRefGoogle Scholar
  17. 17.
    Chu HX, Kim HA, Lee S, Moore JP, Chan CT, Vinh A, et al. Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia. J Cereb Blood Flow Metab. 2014;34:450–9.CrossRefGoogle Scholar
  18. 18.
    Zhao Y, Liu XZ, Tian WW, Guan YF, Wang P, Miao CY. Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. CNS Neurosci Ther. 2014;20:539–47.CrossRefGoogle Scholar
  19. 19.
    Zhao B, Zhang M, Han X, Zhang XY, Xing Q, Dong X, et al. Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism. PLoS One. 2013;8:e85403.CrossRefGoogle Scholar
  20. 20.
    Doll DN, Engler-Chiurazzi EB, Lewis SE, Hu H, Kerr AE, Ren X, et al. Lipopolysaccharide exacerbates infarct size and results in worsened post-stroke behavioral outcomes. Behav Brain Funct. 2015;11(32):32.CrossRefGoogle Scholar
  21. 21.
    Girard S, Brough D, Lopez-Castejon G, Giles J, Rothwell NJ, Allan SM. Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia. 2013;61:813–24.CrossRefGoogle Scholar
  22. 22.
    Wood PL. Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol Res. 1995;17:242–8.CrossRefGoogle Scholar
  23. 23.
    Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87:779–89.CrossRefGoogle Scholar
  24. 24.
    Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288–95.CrossRefGoogle Scholar
  25. 25.
    Stevens SL, Bao J, Hollis J, Lessov NS, Clark WM, Stenzel-Poore MP. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res. 2002;932:110–9.CrossRefGoogle Scholar
  26. 26.
    Weston RM, Jones NM, Jarrott B, Callaway JK. Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injury. J Cereb Blood Flow Metab. 2007;27:100–14.CrossRefGoogle Scholar
  27. 27.
    Bao Dang Q, Lapergue B, Tran-Dinh A, Diallo D, Moreno JA, Mazighi M, et al. High-density lipoproteins limit neutrophil-induced damage to the blood-brain barrier in vitro. J Cereb Blood Flow Metab. 2013;33:575–82.CrossRefGoogle Scholar
  28. 28.
    Lee SR, Wang X, Tsuji K, Lo EH. Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. Neurol Res. 2004;26:854–61.CrossRefGoogle Scholar
  29. 29.
    Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res. 2002;69:1–9.CrossRefGoogle Scholar
  30. 30.
    del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke. 2007;38:646–51.CrossRefGoogle Scholar
  31. 31.
    Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32.PubMedPubMedCentralGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  • Fenghua Chen
    • 1
    • 2
  • Zhongfang Weng
    • 1
    • 2
  • Qinghai Xia
    • 1
  • Catherine Cao
    • 3
  • Rehana K. Leak
    • 4
  • Lihong Han
    • 5
  • Jian Xiao
    • 6
  • Steven H. Graham
    • 1
    • 2
  • Guodong Cao
    • 1
    • 2
    Email author
  1. 1.Department of Neurology, BST S520University of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Geriatric Research, Education and Clinical CenterVeterans Affairs Pittsburgh Healthcare SystemPittsburghUSA
  3. 3.North Allegheny Senior High SchoolPittsburghUSA
  4. 4.Division of Pharmaceutical SciencesDuquesne UniversityPittsburghUSA
  5. 5.Department of BiochemistryBaotou Medical CollegeBaotouChina
  6. 6.Molecular Pharmacology Research CenterWenzhou Medical UniversityZhejianChina

Personalised recommendations